tbuckley/cabot-search huggingface dataset:
AB0388 A Reduced Lean Body Mass is Associated with a More Severe Joint Damage in Patients with Rheumatoid Arthritis (RA)
Authors: R. Gamboa-Cárdenas, M. Ugarte-Gil, F. Zevallos M, Z. Rodriguez B, J. Cucho-V, J. Alfaro L, M. Medina Ch, R. Perich C, C. Pastor-A
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In Rheumatoid Arthritis (RA) alterations in the amount and distribution of fat and lean mass result in abnormal body composition phenotypes probably as a consequence of persistent inflammatory state. Lower lean mass and the sarcopenia phenotype have been associated with disability previously. <h3>Objectives</h3> The aim of this study was to determine whether a reduced Lean Body Mass (LBM) is associated with a more severe joint damage in RA <h3>Methods</h3> A cross-sectional study, conducted in consecutive established RA woman patients seen in our Rheumatology Department between 2012 and 2014. RA was defined using the ACR 1987 criteria. Patients with overlap syndrome (except Sjogren), prosthetic or metallic elements, infections, trauma/ recent surgery, cancer, hospitalized, pregnant or weight&gt;120 kg were excluded. An interview, chart review, physical examination and laboratory tests were performed. All subjects providing written informed consent. LBM was determined by dual X-ray absorptiometry (DXA) and was expressed as the LBM Index (kg/ m<sup>2</sup>). Joint damage (JD) was measure according to Sharp VD Heijde method (erosion, joint space narrowing and total score). The association between LBM and JD was evaluated using Pearson9s correlation. Subsequently, a linear regression model was performed to evaluate the persistence of these association adjusted by age, age at diagnosis, disease duration, Socioeconomic status according to Graffar9s scale, tobacco habit, ACPA title, disease activity using the DAS28 ESR, glucocorticoids use and functional capacity (MHAQ questionnaire) <h3>Results</h3> One hundred and seventy-four women patients were included. The average (SD) age was 57.7 (12.7) years. Disease duration was 14.4 (10.6) years; all patients were mestizo. ACPA title was 768.8 (1357.3) uM/L, DAS28 was 4.8 (1.3), the Sharp VD Heijde total score was 168 (93.6) and the Body Mass Index (BMI) was: 28.19 (4.81) kg/m<sup>2</sup>. The LBM was 6.03 kg/m<sup>2</sup> (0.9) and the percentage of fat Body Mass (FBM) was 38.46 (4.56) In the univariate analysis, according to Pearson correlation Index, a lower LBM was associated with a more total (-0.27, p=0.00); erosion (-0.27, p=0.001) and space narrowing (-0.25, p=0.001) Sharp VDH scores. In the multivariate model adjusted by age, age at diagnosis, disease duration, Graffar9s scale, tobacco, ACPA, DAS28, glucocorticoids use and MHAQ, these correlation persisted (erosion score: B: -0.010, p=0.002; space narrowing score: B: -0.012; p=0.002 and total score: B: -0.006 p=0.001) <h3>Conclusions</h3> A lower Lean Body Mass was associated with a more severe joint damage independently of other risk factors. Strategies aimed at preserving lean muscle mass could have a favorable impact on the course of disease. <h3>Disclosure of Interest</h3> None declared
Efficacy of oxaliplatin and 5-fluorouracil in advanced hepatocarcinoma
Authors: A. Tahri, T. Quang, V. Dien, L. Nam, J. Biset, J. Guillon, F. Tahiri
Journal: Journal of Clinical Oncology (2006)

14143 Background: Hepatocarcinoma (HCC) is one of the commonest malignancies worldwide. Advanced HCC represents one of the most frustrating issue, when further loco-regional therapy is not available for tumor extension, major blood vessel thrombosis or poor liver function. Systemic and palliative treatments are still discouraging. Oxaliplatin (OXA) and 5-Fluorouracil (5-FU) combination has shown in vitro and in vivo activity, moreover prolonged infusion of 5-FU could be useful in preventing DNA repair from OXA. This combination can be an interesting treatment for patients affected by advanced HCC as previously reported (Bearz A. et al, Proc ASCO # 2343, 2001. Frustaci S. et al, Proc ASCO # 1346, 2003). The goal of this work is to evaluate the feasibility, toxicity and response rate of this protocol. Methods: Inclusion criteria were inoperable or metastatic HCC, measurable parameters, PS &lt; 2, creatinine &lt; 1,5 mg/dL, total bilirubin &lt; 4 mg/dL, any previous treatment. Chemotherapy consisted of: OXA 100 mg/m 2 in 2 hrs perfusion; 5-FU 200 mg/m 2 /day as a continuous infusion for 14 days. Cycles were repeated every 2 weeks until progression or grade 3–4 toxicities. Results: From October 2002 to November 2004, 8 patients (pts) (6M, 2F) were treated. Median age was 53 years, 2 pts were affected by hepatitis C (HCV), 3 by hepatitis B (HBV), 2 by both HCV and HBV and 1 by alcoholic cirrhosis. Stage: IVA in 4 pts, IVB in 4. 5 pts were totally untreated and 3 had chemoembolization. Median number of administered cycles for patient was 6 (3–11). We observed haematological toxicity grade 2 in 2 cases, diarrhoea, peripheral neuropathy and nausea grade 2 in 1 case respectively. Partial response was obtained in 4 pts, stable disease in 2, progression in 1, 1 patient is lost to follow-up. Up to now, median duration of response is 6 months. Conclusions: The regimen showed to be feasible tolerable and with interesting response rate for HCC patients not suitable for other therapeutical options. The results are encouraging and warrant a further phase III study. No significant financial relationships to disclose.
PTH-109 Hepatocellular carcinoma: opportunities in primary and secondary care to improve patient outcomes
Authors: L Corless, F Majeed, A West, G Abouda
Journal: Gut (2015)

<h3>Introduction</h3> Hepatocellular carcinoma (HCC) is an increasingly common and devastating consequence of chronic liver disease (CLD). Early diagnosis of CLD provides opportunities to alter disease course and offer surveillance. In our centre, surveillance was historically arranged during general hepatology clinic appointments, which were often overbooked or delayed. We analysed how patients ultimately diagnosed with HCC presented to secondary care, to identify key areas for service improvement. <h3>Method</h3> All patients with a diagnosis of HCC attending our Trust between 1/1/12 and 1/1/14 were included in the data collection including demographics and tumour characteristics, alongside details of the mode of presentation to specialist services, management and clinical outcomes. Next, a nurse-led surveillance clinic (NSC) was instituted to run alongside the hepatology clinic, and performance and satisfaction data collected. <h3>Results</h3> 2/3 of those who developed HCC did so on a background of pre-existing liver disease. In many, HCC was the first presentation to secondary care, but 33% were already under specialist follow up. Of the first presentations, the majority had significant liver disease and 71% also had historically abnormal liver function tests (LFT), but had never been referred to hepatology. No-one in this group was eligible for potentially curative therapy. 25% of patients within secondary care were not on surveillance – all had advanced disease and were only eligible for best supportive care (BSC). Half of patients on surveillance were not monitored in accordance with guidelines, although 1/3 overall were still eligible for curative therapy. However, even where only BSC was appropriate, median survival was significantly improved compared to those presenting for the first time (7 months vs. 1 month). To improve our service, we instituted an NSC for those with compensated cirrhosis. After 1 year, our audit showed no patients lost to follow up, few delays in surveillance, and improved patient satisfaction across all domains. <h3>Conclusion</h3> Most HCC occurred in those with undiagnosed pre-existing liver disease, despite evidence of historically abnormal LFT in over 70% of cases. Failure to investigate abnormal LFT is a missed opportunity to identify potentially reversible disease, or offer surveillance. In these cases, HCC is usually advanced/incurable, with little time to come to terms with the terminal diagnosis. To combat this, we are working with local commissioners and primary care to standardise pathways for abnormal LFT and increase early identification of liver disease. Within secondary care, our surveillance procedures were suboptimal, although treatment options and outcomes were better in this group. In response, we have instituted an NSC, which has performed well in year 1 and is well liked by patients. <h3>Disclosure of interest</h3> None Declared.
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis
Authors: John H Kempen, Michael M Altaweel, Lea T Drye, Janet T Holbrook, Douglas A Jabs, Elizabeth A Sugar, Jennifer E Thorne
Journal: Ophthalmology (2015)
The behavioral high-risk paradigm and bipolar affective disorder, VIII: Serum free cortisol in nonpatient cyclothymic subjects selected by the General Behavior Inventory
Authors: R A Depue, R M Kleiman, P Davis, M Hutchinson, S P Krauss
Journal: American Journal of Psychiatry (1985)

The degree of biologic concordance between bipolar affective disorder and cyclothymia was assessed within a 3-hour protocol of cortisol functioning. Cyclothymic subjects, selected by the General Behavior Inventory, showed cortisol hypersecretion approaching that of subjects with major affective disorders; they also showed poor modulation of cortisol levels over time, the degree of which was related to increased current level of depression and to a chronic, intermittent depressive course. These results not only support the validity of the General Behavior Inventory but also suggest that cyclothymic subjects with a chronic depressive course may experience persistent biologic disturbance similar to that found during episodes of major depression.
PWE-314 Efficacy and complications in the use of self-expanding colonic stents for large bowel obstruction at a single centre: an analysis of 13 years experience
Authors: EL Kershaw, OE Orr, TC Dudding, T Bryant, JS Knight
Journal: Gut (2015)

<h3>Introduction</h3> Self-expandable metal stents (SEMS) may be used in patients presenting with large bowel obstruction (LBO) and offer a less invasive alternative to surgery and thus avoid the potential need for a stoma. <h3>Method</h3> A retrospective analysis of all patients who underwent attempted SEMS placement for LBO between 2001 and 2014 at a university teaching hospital. Patients were identified from the radiology database and hospital coding via the hospital’s informatics system. <h3>Results</h3> Over the 13-year review period, a primary SEMS was attempted in 143 patients, median age 72 (range 25–108) years, sex ratio 83 males: 60 females. Indications for SEMS were palliative treatment of colorectal cancer (CRC) 101; as bridging prior to resectional surgery for CRC 14; extrinsic compression in 19 and for benign disease in 8 patients. SEMS placement was successful in 110 (77%) patients: in 83 (82%) palliative; 13 (93%) bridging; 12 (63%) compression and 2 (25%) benign groups. 85% of SEMS were placed in the distal colon. In the bridged patients 54% did not require a stoma at subsequent surgery. 91(83%) patients successfully stented had no complication. Of the complications that occurred, 13(15.7%) occurred in palliative, 3(23.1%) bridging, and 3(25%) compression groups. Early complications (&lt;48hrs) occurred in 8 patients: 3 perforations; 4 failures to open; 1 migration and 1 PR bleed. There was 1 death and 7 proceeded to surgery. There were 6 late complications (&lt;1 month): 5 perforations and 1 reobstruction, of which there were 2 deaths and 4 had surgery. Delayed complications (&gt;1 month) occurred in 4 patients, 3 required surgery. Overall median survival post SEMS was 212 days. According to indication for SEMS, 30- and 90-day survival was respectively: palliative 81.2% and 68.2%; bridging 92.3%; compressive 50% and 33.3% and benign 100%. Median (IQR) survival was: palliative 205 (49–425); bridging 766 (408–960) and compression 27 (12–158) days. <h3>Conclusion</h3> The commonest indication for SEMS placement was malignant LBO from CRC. In palliative patients it has a good success rate and avoids the need for surgery in patients with a limited median survival. As a bridge to surgery in patients undergoing subsequent surgery it has a high success rate but does not always avoid the need for a stoma. <h3>Disclosure of interest</h3> None Declared.
One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience
Authors: JP Laporte, L Douay, M Lopez, M Labopin, JP Jouet, S Lesage, J Stachowiak, L Fouillard, F Isnard, MP Noel-Walter
Journal: Blood (1994)
High Esophageal Cancer Rates in Humans and Chickens in North China
Authors: Robert W. Miller
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article High Esophageal Cancer Rates in Humans and Chickens in North China Get access Robert W. Miller, M.D. Robert W. Miller, M.D. Epidemiology Branch National Cancer InstituteBethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 3, March 1975, Page 535, https://doi.org/10.1093/jnci/54.3.535 Published: 01 March 1975
AB0791 Why Do Patients with Axial Spondyloarthritis (AXSPA) Perform Little Aerobic Exercise? A Study of Perceived Barriers and Benefits in 153 Axspa Patients
Authors: S. Fabre, A. Molto, S. Kreis, S. Dadoun, C. Hudry, B. Fautrel, E. Pertuiset, L. Gossec
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Regular exercise is considered a cornerstone of axSpA treatment, together with medication (1). However, only around half the patients reach the levels of physical activity recommended for health-enhancement and very few regularly perform aerobic exercise (2). Understanding why could help motivate axSpA patients to exercise more. <h3>Objectives</h3> To explore the benefits and barriers to physical exercise in axSpA patients. <h3>Methods</h3> A cross-sectional study was performed in two tertiary care hospitals and one office-based practice in France (2). Patients had definite axSpA according to the rheumatologist. Auto-questionnaires evaluating the frequency and type of aerobic exercise, and perceived benefits of and barriers to exercising through the Exercise Benefits/Barriers Score (EBBS) (3), were collected. EBBS comprises 43 items categorised into 5 subscales for benefits (life enhancement, physical performance, psychological outlook, social interaction and preventive health) and 4 subscales for barriers (exercise milieu, time expenditure, physical exertion, family discouragement). Analyses were comparative between men and women. <h3>Results</h3> In all, 153 patients were analysed: mean age, 45.7±11.1 years, mean disease duration 14.2±9.7 yrs, mean BASDAI (0-100) 36.7±20.7, mean BASFI (0-100) 28.1±25.5, mean BMI 25.2±4.8 kg/m<sup>2</sup>; 56.2% were men. The main benefits of exercise (for which more than 90% of patients agreed or strongly agreed with the item) were all in the 'physical performance' subscale. Highest agreement was found for: improving functioning of cardiovascular system (94.8%), increasing muscle strength (93.5%), level of physical fitness (92.8%), stamina (90.9%), and for women: flexibility (91.0%). The three main barriers were 'people looking funny in exercise clothes' (87.6%), 'too few places to exercise' (80.4%), and 'lack of encouragement from family members' (81.1%). Results were similar for men and women. <h3>Conclusions</h3> The main barriers to exercising for axSpA patients were 'exercise milieu' problems and 'family discouragement' while the main perceived benefit was a better physical performance. These findings could be helpful when encouraging physical activity in axSpA patients. <h3>References</h3> Braun J et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896–904. Fabre S, et al. Do Patients with Axial Spondyloarthritis (AxSpA) Perform Enough Physical Activity? a Cross-Sectional Study of 207 Patients. Arthritis Rheum 2014, 66(suppl):S1125. Sechrist KR, et al. Development and psychometric evaluation of the exercise benefits/barriers scale, Res Nurs Health 1987;10:357-65. <h3>Disclosure of Interest</h3> None declared
PWE-376 Endocuff-visiontm: impact on colonoscopist performance during screening
Authors: ZP Tsiamoulos, R Misra, K Patel, L Bourikas, S Thomas-Gibson, A Haycock, N Suzuki, BP Saunders
Journal: Gut (2015)

<h3>Introduction</h3> Although colonoscopy is considered the optimal procedure for bowel cancer screening, it remains an imperfect tool for cancer prevention, due to missed adenomas and early cancers. The Endocuff is a simple device attached at the end of the colonoscope that opens up the field of view by retracting folds during withdrawal. Little is known regarding the Endocuff’s impact on a colonoscopist’s performance. <h3>Method</h3> The aim of this study was to evaluate the impact of the Endocuff-vision<sup>TM</sup>(ARC Design Ltd, UK) on the quality indicators for each operator. A prospective observational evaluation study was performed from April 2013 to September 2014, divided in three consecutive periods: pre-cuff (no device used), during-cuff (device used) and post-cuff (no device used). Four screening endoscopists (BPS, STG, NS, AH) utilised the Endocuff-vision<sup>TM</sup>at their own discretion when device was available to them. Quality colonoscopy indicators {(Adenoma Detection Rate (ADR), Mean number of adenomas per procedure (MAP), Caecal intubation time (CIT)} were analysed (t-test two sample assuming equal variances) in equivalent number of procedures. The total number of procedures performed was 399, 133 per period (BPS/26, STG/53, NS/31, AH/23). <h3>Results</h3> The mean ADR was 55.13% in the pre-cuff period, 68.98% in the during-cuff period and 61.74% in the post-cuff period. All four operators showed significant improvement in detection when using the device, which resulted in an overall increased ADR of <b>13.8% </b>(p &lt; 0.05). During the post-cuff period, the detection performance of the three endoscopists declined while maintaining a high detection rate. The mean MAP was 1.2 in the pre-cuff period, 2.2 in the during-cuff period and 1.55 in the post-cuff period. The mean MAP increased significantly in all four operators at the during-cuff period (<b>83%</b>, p &lt; 0.05). During the post-cuff, 3 endoscopists returned almost to the baseline MAP pre-cuff level. The mean CIT was 9.66min in the pre-cuff period, 7.5min in the during-cuff period and 9.54min in the post-cuff period. A decrease in mean CIT was featured (<b>22.36%</b>, p &lt; 0.005) to all operators when using the device, returning to about the pre-cuff levels afterwards. No complications were reported from the use of the Endocuff-vision although it was electively removed in 4 cases with severe sigmoid colon diverticulosis and one case due to anal discomfort. <h3>Conclusion</h3> In this study, use of the Endocuff-vision<sup>TM</sup>improved overall performance by making colonoscopy a quicker (CIT) and more efficient (MAP/ADR) procedure. Further randomised evaluation of this simple novel device is warranted. <h3>Disclosure of interest</h3> None Declared.
Antibodies against human neutrophil LECAM-1 (LAM-1/Leu-8/DREG-56 antigen) and endothelial cell ELAM-1 inhibit a common CD18-independent adhesion pathway in vitro
Authors: TK Kishimoto, RA Warnock, MA Jutila, EC Butcher, C Lane, DC Anderson, CW Smith
Journal: Blood (1991)
A serum microRNA biomarker panel for detection of gastric cancer.
Authors: Jimmy So, Ruiyang Zou, Lihan Zhou, Heng-Phon Too, Feng Zhu, Yik Ying Teo, Celestial T Yap, Sun Young Rha, Koji Kono, Joanne Yoong, Khay-Guan Yeoh, Wei-Peng Yong
Journal: Journal of Clinical Oncology (2015)

4060 Background: Gastric cancer is the 2nd most common cause of cancer deaths worldwide. Currently, endoscopy is the only reliable method for early diagnosis. However, the invasiveness and cost limit its usage as a screening test. MicroRNAs (miRNAs) have been shown to be important in the pathogenesis of cancers. They are exceptionally stable in body fluids, making them potential noninvasive biomarker for cancers. Methods: We screened 600 miRNAs using our MiRXES qPCR technology in the sera of 236 gastric cancer subjects and 236 matched high risk subjects, serving as the discovery set. 191 miRNAs were reliably detected in all the serum samples, out of which 75 informative ones were identified to be significantly (false discovered corrected P value lower than 0.01) altered between gastric cancer and high risk subjects. Multivariate miRNA biomarker panels were then formulated by sequence forward floating search and support vector machine using all the quantitative data obtained for the expression of 191 miRNAs. Results: Multiple iterations of two-fold cross-validation were performed in silico where the panels with 8 or more miRNAs consistently achieved high accuracy [areas under the curve (AUC) ≥ 0.87 in the receiver operating characteristic (ROC) curve]. A 24-miRNA model was optimized based on the discovery set [AUC = 0.92 ( 95% Confidence Interval [CI]: 0.88-0.95)] and validated in two blinded studies with fixed algorithm and threshold definition; Korean case-control cohort (n = 129, 74 cancer cases) and Singaporean Chinese case-control cohort (n = 89, 20 cancer cases). The 24-miR panel showed 90% sensitivity and 81% specificity in the Korean cohort (AUC = 0.91 (95% CI: 0.86-0.96)] and had 90% sensitivity and 75% specificity in the Singaporean Chinese cohort [AUC = 0.89 (95% CI: 0.79-0.99)]. Importantly, the 24-miR panel was able to distinguish stage 1 and 2 gastric cancer in both Korean [AUC = 0.88 (95% CI: 0.81-0.96)] and Singaporean Chinese [AUC = 0.91 (95% CI: 0.80-1.00)] cohorts. Conclusions: We have identified a serum miRNA panel which can confidently differentiate patients with gastric cancer including the early-staged cancers from controls. This may be able to serve as a non-invasive screening test for gastric cancer which warrants study in larger cohorts.
Vaccine therapy in asthma.
Authors: H BJORKMAN
Journal: BMJ (1966)

Mumps of the HeartDeath from congestive cardiac failure eight months after probable mumps is sufficiently rare to attract attention.Nevertheless, a report by W. C. Roberts and S. M. Fox' leaves no doubt about the correctness of the diagnosis, while necropsy showed hypertrophy of the heart and the histological changes of diffuse interstitial myocardial fibrosis.
Three-Phase 99mTc-MDP Bone Scintigraphy and SPECT/CT in Pediatric Pseudodystrophy
Authors: Sharjeel Usmani, Satish Panchadar, Anwar al Banna
Journal: Clinical Nuclear Medicine (2015)

Pseudodystrophy is a rare condition clinically resembling reflex sympathetic dystrophy. Distinction between both disorders is based on clinical features and bone scintigraphy. We report a case of 12-year-old girl presented with pain, swelling, and functional impairment of left foot after minor trauma. Clinical assessment revealed atrophy of left calf, cyanosis and coldness of left foot. Laboratory investigations were normal. X-ray and MRI of the foot were unremarkable. Bone scintigraphy showed hypoperfusion and diffusely reduced tracer uptake in the left lower leg and left foot. Diagnosis of pseudodystrophy was made on the basis of history, clinical examination, and bone scintigraphy findings.
Effects of Feeding Thiouracil on Thyroid Glands of Rats
Authors: Wollman, Seymour H.
Journal: JNCI Journal of the National Cancer Institute (1961)

Journal Article Effects of Feeding Thiouracil on Thyroid Glands of Rats Get access Seymour H. Wollman Seymour H. Wollman Laboratory of Physiology, National Cancer Institute,3Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 26, Issue 2, February 1961, Pages 473–487, https://doi.org/10.1093/jnci/26.2.473 Published: 01 February 1961 Article history Received: 25 August 1960 Published: 01 February 1961